Guardian Pharmacy Services Class A (GRDN) closed at $40.69 on October 30, 2026, up 0.6% from the previous close, on volume of 306,922 shares (30-day average 507,986).
Data as of October 30, 2026.
30-Oct-2026
Business Wire (Wed, 21-Oct 4:30 PM ET)
Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy
Business Wire (Tue, 1-Sep 4:30 PM ET)
Business Wire (Wed, 19-Aug 4:30 PM ET)
Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance
Business Wire (Thu, 6-Aug 4:05 PM ET)
Market Chameleon (Fri, 20-Mar 6:17 AM ET)
Market Chameleon (Thu, 19-Mar 4:16 AM ET)
Guardian Pharmacy Services Inc is a pharmacy services company providing technology-enabled services to help residents of long-term health care facilities (LTCFs) adhere to appropriate drug regimens, reducing the cost of care and improving clinical outcomes. The Company provides high-touch clinical, drug dispensing, and administration services tailored to residents in assisted living facilities, behavioral health facilities, and group homes, while also serving residents in all types of LTCFs. It partners with residents, LTCFs, and health plan payors to help reduce errors in drug administration, manage drug regimens, and improve adherence. The Company derives its revenue mainly from the sale of pharmaceutical and medical products.
Guardian Pharmacy Services Class A trades on the NYSE stock market under the symbol GRDN.
As of October 30, 2026, GRDN stock price climbed to $40.69 with 306,922 million shares trading.
GRDN has a beta of 0.44, meaning it tends to be less sensitive to market movements. GRDN has a correlation of 0.02 to the broad based SPY ETF.
GRDN has a market cap of $2.58 billion. This is considered a Mid Cap stock.
Last quarter Guardian Pharmacy Services Class A reported $352 million in Revenue and $.29 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that GRDN belongs to (by Net Assets): VTI, IWM, VXF, IWO, FPX.
GRDN has outperformed the market in the last year with a price return of +43.7% while the SPY ETF gained +12.3%. However, in the short term, GRDN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -1.2% vs +2.1% return in SPY. But in the last 2 weeks, GRDN shares have fared better than the market returning +3.1% compared to SPY -1.0%.
GRDN support price is $39.37 and resistance is $41.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRDN shares will trade within this expected range on the day.
